Novo Nordisk A/S (VIE:NNO2)

Market Cap	224.99B
Revenue (ttm)	42.26B
Net Income (ttm)	13.89B
Shares Out	n/a
EPS (ttm)	3.12
PE Ratio	16.19
Forward PE	15.88
Dividend	1.56 (3.09%)
Ex-Dividend Date	Aug 15, 2025

Volume	5,287
Average Volume	10,151
Open	50.54
Previous Close	51.51
Day's Range	50.41 - 51.40
52-Week Range	36.00 - 90.35
Beta	n/a
RSI	65.32
Earnings Date	Feb 4, 2026

About Novo Nordisk

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin...

• Industry: Pharmaceutical Preparations
• Founded: 1923
• Employees: 77,349
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: NNO2

Financial Performance

In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.

Financial numbers in DKK